ロード中...
The Ins and Outs of Bcr-Abl Inhibition
The development of inhibitors against Abl has changed the landscape for the treatment of chronic myelogenous leukemia (CML) and cancer in general. Beginning with the monumental discovery and approval of imatinib for CML, a second generation of inhibitors, nilotinib and dasatinib, has now gained appr...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3513788/ https://ncbi.nlm.nih.gov/pubmed/23226582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1947601912462126 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|